Carcinogenic Properties of Proteins with Pro-inflammatory Activity from Streptococcus Infantarius (formerly S.bovis)
Overview
Authors
Affiliations
Several studies reported linkage between bacterial infections and carcinogenesis. Streptococcus bovis was traditionally considered as a lower grade pathogen frequently involved in bacteremia and endocarditis. This bacterium became important in human health as it was shown that 25-80% of patients who presented a S.bovis bacteremia had also a colorectal tumor. Moreover, in previous experiments, we demonstrated that S.bovis or S.bovis wall extracted antigens (WEA) were able to promote carcinogenesis in rats. The aim of the present study was: (i) to identify the S.bovis proteins responsible for in vitro pro-inflammatory properties; (ii) to purify them; (iii) to examine their ability to stimulate in vitro IL-8 and COX-2 expression by human colon cancer cells; and (iv) to assess in vivo their pro-carcinogenic potential in a rat model of colon carcinogenesis. The purified S300 fraction, as determined by proteomic analysis, contained 72 protein spots in two-dimensional gel electrophoresis representing 12 different proteins able to trigger human epithelial colonic Caco-2 cells and rat colonic mucosa to release CXC chemokines (human IL-8 or rat CINC/GRO) and prostaglandins E2, correlated with an in vitro over-expression of COX-2. Moreover, these proteins were highly effective in the promotion of pre-neoplastic lesions in azoxymethane-treated rats. In the presence of these proteins, Caco-2 cells exhibited enhanced phosphorylation of the three classes of MAP kinases. Our results show a relationship between the pro-inflammatory potential of S.bovis proteins and their pro-carcinogenic properties, confirming the linkage between inflammation and colon carcinogenesis. These data support the hypothesis that colonic bacteria can contribute to cancer development particularly in chronic infection/inflammation diseases where bacterial components may interfere with cell function.
Shanti I, Samardali M, Gebremedhen A Cureus. 2024; 16(11):e74264.
PMID: 39712796 PMC: 11663499. DOI: 10.7759/cureus.74264.
Warner D, Mehta A Gut Microbiome (Camb). 2024; 5:e9.
PMID: 39703539 PMC: 11658940. DOI: 10.1017/gmb.2024.11.
Taya S, Dissook S, Ruangsuriya J, Yodkeeree S, Boonyapranai K, Chewonarin T Nutrients. 2024; 16(20).
PMID: 39458500 PMC: 11510544. DOI: 10.3390/nu16203506.
Alzahabi M, Haddad J, Bishai S JSES Rev Rep Tech. 2024; 4(3):559-562.
PMID: 39157225 PMC: 11329031. DOI: 10.1016/j.xrrt.2024.05.001.
Kwao-Zigah G, Bediako-Bowan A, Boateng P, Aryee G, Abbang S, Atampugbire G Cancer Control. 2024; 31:10732748241263650.
PMID: 38889965 PMC: 11186396. DOI: 10.1177/10732748241263650.